Fol. Biol. 2016, 62, 120-130
https://doi.org/10.14712/fb2016062030120
The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes
References
1. 2008) Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 15, 109-116.
< , B. M., Kassem, M. (https://doi.org/10.1038/sj.gt.3303067>
2. 2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822.
< , S., Pittenger, M. F. (https://doi.org/10.1182/blood-2004-04-1559>
3. 1999) Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand. J. Immunol. 49, 237-243.
< , E., Andersson, B. (https://doi.org/10.1046/j.1365-3083.1999.00470.x>
4. 1997) Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27, 71-76.
< , A., Licenziati, S., Corulli, M., Canaris, A. D., De Francesco, M. A., Fiorentini, S., Peroni, L., Fallacara, F., Dima, F., Balsari, A., Turano, A. (https://doi.org/10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O>
5. 2001) Interferon-γ and interleukin- 6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 98, 1594-1600.
< , J., Dickinson, A. M., Norden, J., Taylor, P. R., Jackson, G. H., Middleton, P. G. (https://doi.org/10.1182/blood.V98.5.1594>
6. 2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843.
< , M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., Gianni, A. M. (https://doi.org/10.1182/blood.V99.10.3838>
7. 2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
< , M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., Horwitz, E. (https://doi.org/10.1080/14653240600855905>
8. 2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32, 605-615.
< , L., Watford, W. T., Ramos, H. L., Laurence, A., Vahedi, G., Wei, L., Takahashi, H., Sun, H. W., Kanno, Y., Powrie, F., O’Shea, J. J. (https://doi.org/10.1016/j.immuni.2010.05.003>
9. 1996) CD69 expression after antigenic stimulation. Cytometry 23, 260-261.
, D. C., Evans, T. G. (
10. 2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-2827.
< , S., Soeiro, I., Dyson, P. J., Lam, E. W., Dazzi, F. (https://doi.org/10.1182/blood-2004-09-3696>
11. 2005) Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928-934.
< , M. E., Maitra, B., Szekely, E., Koc, O. N. (https://doi.org/10.1016/j.exphem.2005.05.002>
12. 2012) Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin- 10, interferon-γ, and indoleamine 2,3-dioxygenase. Cell Transplant. 21, 971-984.
< , H. S., Lin, C. H., Hsu, W. T., Liu, Y. R., Hsu, R. B., Chiang, B. L., Tseng, W. Y., Chen, M. F., Wu, K. K., Lee, C. M. (https://doi.org/10.3727/096368911X627525>
13. 2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57, 11-20.
< , K., Tammik, L., Sundberg, B., Haynesworth, S. E., Ringdén, O. (https://doi.org/10.1046/j.1365-3083.2003.01176.x>
14. 2004) Mesenchymal stem cell inhibit the expression of CD25 (IL-2 receptor) and CD38 on phytohaemagglutinin activated lymphocytes. Scand. J. Immunol. 60, 307-315.
< , K., Gotherstrom, C., Rasmusson, I., Seidel, C., Sundberg, B., Sundin, M., Rosendahl, K., Tammik, C., Ringdén, O. (https://doi.org/10.1111/j.0300-9475.2004.01483.x>
15. 2005) Mesenchymal stem cells: progress toward promise. Cytotherapy 7, 36-45.
< , K., Pittenger, M. F. (https://doi.org/10.1016/S1465-3249(05)70787-8>
16. 2007) Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262, 509-525.
< , K., Ringdén, O. (https://doi.org/10.1111/j.1365-2796.2007.01844.x>
17. 2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586.
< , K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., Dini, G., Egeler, R. M., Bacigalupo, A., Fibbe, W., Ringdén, O. (https://doi.org/10.1016/S0140-6736(08)60690-X>
18. 2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen- specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90, 516-525.
, R., Podestà, M., Moretta, A., Cometa, A., Comoli, P., Montagna, D., Daudt, L., Ibatici, A., Piaggio, G., Pozz, S., Frassoni, F., Locatelli, F. (
19. 2013) Multipotent stromal cells skew monocytes towards an antiinflammatory interleukin-10-producing phenotype by induction of interleukin-6. Haematologica 98, 888-895.
< , S. M., Geutskens, S. B., Fibbe, W., Roelofs, H. (https://doi.org/10.3324/haematol.2012.078055>
20. 2007) Advances in the understanding of acute graft-versus-host disease. Br. J. Haematol. 137, 3-19.
< , E. S., Hill, G. R. (https://doi.org/10.1111/j.1365-2141.2007.06510.x>
21. 2009) Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11, 570-583.
< , M., Rouas, R., Raicevic, G., Boufker, H. I., Lewalle, P., Meuleman, N., Bron, D., Toungouz, M., Martiat, P., Lagneaux, L. (https://doi.org/10.1080/14653240903079377>
22. 2012) JAKs and STATs in immunoregulation and immune-mediated disease. Immunity 36, 542-550.
< , J. J., Plenge, R. (https://doi.org/10.1016/j.immuni.2012.03.014>
23. 2008) The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell. Immunol. 251, 131-136.
< , R., Tong, C. K., Seow, H. F., Vidyadaran, S., Dazz, F. (https://doi.org/10.1016/j.cellimm.2008.04.009>
24. 2005) Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305, 33-41.
< , I. Ringdén, O., Sundberg, B., Le Blanc, K. (https://doi.org/10.1016/j.yexcr.2004.12.013>
25. 2004) Comparative analysis of lymphocyte activation markers expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune functions. J. Immunol. Methods 293, 127-142.
< , M., Eirikis, E., Davis, C., Davis, H. M., Prabhakar, U. (https://doi.org/10.1016/j.jim.2004.07.006>
26. 2011) Mesenchymal stromal cells as treatment for chronic GVHD. Bone Marrow Transplant. 46, 163-164.
< , O., Keating, A. (https://doi.org/10.1038/bmt.2010.275>
27. 2007) Regulation of T cell homeostasis by JAK and STATs. Arch. Immunol. Ther. Exp. 55, 231-245.
< , J. A., Nagy, Z. S., Cheng, H., Stepkowski, S. M., Kirken, R. (https://doi.org/10.1007/s00005-007-0030-x>
28. 2012) Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-κB signaling. J. Cell. Mol. Med. 16, 1232-1244.
< , F. S., Haddad, R., de Farias, K. C. R. M., Souza, A. P. A., Palma, P. V., Araujo, A. G., Orellana, M. D., Voltarelli, J. C., Covas, D. T., Zago, M. A., Panepucci, R. A. (https://doi.org/10.1111/j.1582-4934.2011.01391.x>
29. 2007) JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059-20063.
< , C., Levy, D. E., Decker, T. (https://doi.org/10.1074/jbc.R700016200>
30. 2009) HSCT recipients have specific tolerance to MSC but not to the MSC donor. J. Immunother. 32, 755-764.
< , M., Barrett, A. J., Ringden, O., Uzunel, M., Lonnies, H., Dackland, A. L., Christensson, B., Le Blanc, K. (https://doi.org/10.1097/CJI.0b013e3181ab1807>
31. 2011) Interleukin- 6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin. Cancer Res. 17, 77-88.
< , I., Koyama, M., Liu, C., Toubai, T., Thomas, D., Evers, R., Chockley, P., Nieves, E., Sun, Y., Lowler, K. P., Malter, C., Nishimoto, N., Hill, G. R., Reddy, P. (https://doi.org/10.1158/1078-0432.CCR-10-1198>
32. 2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397.
< , W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., Guinan, E. C. (https://doi.org/10.1097/01.TP.0000045055.63901.A9>
33. 1997) Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cells suspensions. Allergy 52, 465-469.
< , T., Boeker, M., Kapp, A. (https://doi.org/10.1111/j.1398-9995.1997.tb01031.x>
34. 2008) Allogeneic mesenchymal stem cells and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology 47, 22-30.
< , Z. H., Li, X. Y., Ding, J., Jia, J. F., Zhu, P. (https://doi.org/10.1093/rheumatology/kem284>